Welcome to LookChem.com Sign In|Join Free

CAS

  • or

16909-09-4

Post Buying Request

16909-09-4 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

16909-09-4 Usage

General Description

2,4-Dimethoxycinnamic acid is an organic compound that belongs to the class of cinnamic acids. It is composed of a cinnamic acid core with two methoxy substituents on the benzene ring. 2,4-DIMETHOXYCINNAMIC ACID is commonly used as a building block in the synthesis of various pharmaceuticals and agrochemicals. It is also known for its antioxidant properties, which make it a potential candidate for use in the food and beverage industry. Additionally, 2,4-dimethoxycinnamic acid has been studied for its potential anti-inflammatory and antibacterial effects, showing promise for the development of new therapeutic agents. Overall, this compound has multiple applications in various industries and has potential for further research and development.

Check Digit Verification of cas no

The CAS Registry Mumber 16909-09-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,6,9,0 and 9 respectively; the second part has 2 digits, 0 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 16909-09:
(7*1)+(6*6)+(5*9)+(4*0)+(3*9)+(2*0)+(1*9)=124
124 % 10 = 4
So 16909-09-4 is a valid CAS Registry Number.
InChI:InChI=1/C11H12O4/c1-14-9-5-3-8(4-6-11(12)13)10(7-9)15-2/h3-7H,1-2H3,(H,12,13)/b6-4+

16909-09-4Relevant articles and documents

2-Hydroxy-4-methoxy-trans-cinnamic Acid as a Precursor of Herniarin in Artemisia dracunculus

Hofer, Otmar,Szabo, Geza,Greger, Harald

, p. 1219 - 1222 (1986)

The isolation of (E)-2-hydroxy-4-methoxycinnamic acid (1) from Artemisia dracunculus L. supports strongly the assumption that this compound is an intermediate in the biosynthesis of 7-methoxycoumarin (herniarin, 3).The structure of the UV-unstable compound 1 was derived from 1H-NMR data and by comparison of the stable dimethylated derivative with synthetic (E)-2,4-dimethoxycinnamic acid methyl ester (2). - Keywords: Coumarins; Biosynthesis; Herniarin; Artemisia dracunculus; Compositae

Design, synthesis and biological evaluation of (E)-5-styryl-1,2,4-oxadiazoles as anti-tubercular agents

Atmaram Upare, Abhay,Gadekar, Pradip K.,Sivaramakrishnan,Naik, Nishigandha,Khedkar, Vijay M.,Sarkar, Dhiman,Choudhari, Amit,Mohana Roopan

supporting information, p. 507 - 512 (2019/02/19)

Cinnamic acid and its derivatives are known for anti-tubercular activity. The present study reports the synthesis of cinnamic acid derivatives via bioisosteric replacement of terminal carboxylic acid with “oxadiazole”. A series of cinnamic acid derivatives (styryl oxadiazoles) were designed and synthesized in good yields by reaction of substituted cinnamic acids (2, 15a-15s) with amidoximes. The synthesized styryl oxadiazoles were evaluated in vitro for anti-tubercular activity against Mycobacterium tuberculosis (Mtb) H37Ra strain. The structure-activity relationship (SAR) study has identified several compounds with mixed anti-tubercular profiles. The compound 32 displayed potent anti-tubercular activity (IC50 = 0.045 μg/mL). Molecular docking studies on mycobacterial enoyl-ACP reductase enzyme corroborated well with the experimental findings providing a platform for structure based hit-to-lead development.

Development of sulfonamides incorporating phenylacrylamido functionalities as carbonic anhydrase isoforms I, II, IX and XII inhibitors

Angapelly, Srinivas,Ramya, P.V. Sri,Angeli, Andrea,Del Prete, Sonia,Capasso, Clemente,Arifuddin, Mohammed,Supuran, Claudiu T.

, p. 5726 - 5732 (2017/10/09)

A series of novel sulfonamides incorporating phenylacrylamido functionalities were synthesized and investigated for the inhibition of the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1). The physiologically and pharmacologically relevant human (h) isoforms hCA I and II (cytosolic isozymes), as well as the transmembrane tumor-associated hCA IX and XII were included in the study. These compounds showed low nanomolar or sub-nanomolar inhibition constants against hCA II (KIs in the range of 0.50–50.5 nM), hCA IX (KIs of 1.8–228.5 nM), and hCA XII (KIs of 3.5–96.2 nM) being less effective as inhibitors of the off target isoform hCA I. A detailed structure–activity relationship study demonstrates that the nature and position of substituents present on the aromatic part of the scaffold strongly influence the inhibition of CA isoforms. As hCA II, IX and XII are involved in pathologies such as glaucoma and hypoxic, and metastatic tumors, compounds of the type reported in this work may be useful preclinical candidates.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 16909-09-4